- Home
- CBIO vs FLC Comparison
CBIO vs FLC Comparison
Compare CBIO & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- FLC
- Stock Information
- Founded
- CBIO 2003
- FLC 2003
- Country
- CBIO United States
- FLC United States
- Employees
- CBIO N/A
- FLC N/A
- Industry
- CBIO
- FLC Trusts Except Educational Religious and Charitable
- Sector
- CBIO
- FLC Finance
- Exchange
- CBIO Nasdaq
- FLC Nasdaq
- Market Cap
- CBIO 209.8M
- FLC 186.8M
- IPO Year
- CBIO N/A
- FLC N/A
- Fundamental
- Price
- CBIO $12.35
- FLC $17.65
- Analyst Decision
- CBIO Strong Buy
- FLC
- Analyst Count
- CBIO 5
- FLC 0
- Target Price
- CBIO $25.60
- FLC N/A
- AVG Volume (30 Days)
- CBIO 111.3K
- FLC 37.8K
- Earning Date
- CBIO 11-23-2025
- FLC 01-01-0001
- Dividend Yield
- CBIO N/A
- FLC 6.64%
- EPS Growth
- CBIO N/A
- FLC N/A
- EPS
- CBIO N/A
- FLC N/A
- Revenue
- CBIO N/A
- FLC N/A
- Revenue This Year
- CBIO N/A
- FLC N/A
- Revenue Next Year
- CBIO N/A
- FLC N/A
- P/E Ratio
- CBIO N/A
- FLC N/A
- Revenue Growth
- CBIO N/A
- FLC N/A
- 52 Week Low
- CBIO $9.81
- FLC $12.62
- 52 Week High
- CBIO $21.40
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- CBIO 49.46
- FLC 49.63
- Support Level
- CBIO $12.30
- FLC $17.46
- Resistance Level
- CBIO $12.84
- FLC $17.70
- Average True Range (ATR)
- CBIO 0.72
- FLC 0.16
- MACD
- CBIO 0.07
- FLC -0.01
- Stochastic Oscillator
- CBIO 66.55
- FLC 43.18
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.